SARS-CoV-2 host cell entry: an in silico investigation of potential inhibitory roles of terpenoids
Background Targeting viral cell entry proteins is an emerging therapeutic strategy for inhibiting the first stage of SARS-CoV-2 infection. In this study, 106 bioactive terpenoids from African medicinal plants were screened through molecular docking analysis against human angiotensin-converting enzyme 2 (hACE2), human transmembrane protease serine 2 (TMPRSS2), and the spike (S) proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV. In silico absorption-distribution-metabolism-excretion-toxicity (ADMET) and drug-likeness prediction, molecular dynamics (MD) simulation, binding free energy calculations, and clustering analysis of MD simulation trajectories were performed on the top docked terpenoids to respective protein targets. Results The results revealed eight terpenoids with high binding tendencies to the catalytic residues of different targets. Two pentacyclic terpenoids (24-methylene cycloartenol and isoiguesteri) interacted with the hACE2 binding hotspots for the SARS-CoV-2 spike protein, while the abietane diterpenes were found accommodated within the S1-specificity pocket, interacting strongly with the active site residues TMPRSS2. 3-benzoylhosloppone and cucurbitacin interacted with the RBD and S2 subunit of SARS-CoV-2 spike protein respectively. These interactions were preserved in a simulated dynamic environment, thereby, demonstrating high structural stability. The MM-GBSA binding free energy calculations corroborated the docking interactions. The top docked terpenoids showed favorable drug-likeness and ADMET properties over a wide range of molecular descriptors. Conclusion The identified terpenoids from this study provides core structure that can be exploited for further lead optimization to design drugs against SARS-CoV-2 cell-mediated entry proteins. They are therefore recommended for further in vitro and in vivo studies towards developing entry inhibitors against the ongoing COVID-19 pandemic..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of Genetic Engineering and Biotechnology - 19(2021), 1 vom: 05. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gyebi, Gideon A. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
ACE2 |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1186/s43141-021-00209-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR044758774 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044758774 | ||
| 003 | DE-627 | ||
| 005 | 20230519182818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210806s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43141-021-00209-z |2 doi | |
| 035 | |a (DE-627)SPR044758774 | ||
| 035 | |a (SPR)s43141-021-00209-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q ASE |
| 100 | 1 | |a Gyebi, Gideon A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 host cell entry: an in silico investigation of potential inhibitory roles of terpenoids |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Background Targeting viral cell entry proteins is an emerging therapeutic strategy for inhibiting the first stage of SARS-CoV-2 infection. In this study, 106 bioactive terpenoids from African medicinal plants were screened through molecular docking analysis against human angiotensin-converting enzyme 2 (hACE2), human transmembrane protease serine 2 (TMPRSS2), and the spike (S) proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV. In silico absorption-distribution-metabolism-excretion-toxicity (ADMET) and drug-likeness prediction, molecular dynamics (MD) simulation, binding free energy calculations, and clustering analysis of MD simulation trajectories were performed on the top docked terpenoids to respective protein targets. Results The results revealed eight terpenoids with high binding tendencies to the catalytic residues of different targets. Two pentacyclic terpenoids (24-methylene cycloartenol and isoiguesteri) interacted with the hACE2 binding hotspots for the SARS-CoV-2 spike protein, while the abietane diterpenes were found accommodated within the S1-specificity pocket, interacting strongly with the active site residues TMPRSS2. 3-benzoylhosloppone and cucurbitacin interacted with the RBD and S2 subunit of SARS-CoV-2 spike protein respectively. These interactions were preserved in a simulated dynamic environment, thereby, demonstrating high structural stability. The MM-GBSA binding free energy calculations corroborated the docking interactions. The top docked terpenoids showed favorable drug-likeness and ADMET properties over a wide range of molecular descriptors. Conclusion The identified terpenoids from this study provides core structure that can be exploited for further lead optimization to design drugs against SARS-CoV-2 cell-mediated entry proteins. They are therefore recommended for further in vitro and in vivo studies towards developing entry inhibitors against the ongoing COVID-19 pandemic. | ||
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ACE2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a TMPRSS2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Spike protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Terpenoids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Abietane diterpenes: Molecular docking |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ogunyemi, Oludare M. |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Ibrahim M. |e verfasserin |4 aut | |
| 700 | 1 | |a Ogunro, Olalekan B. |e verfasserin |4 aut | |
| 700 | 1 | |a Adegunloye, Adegbenro P. |e verfasserin |4 aut | |
| 700 | 1 | |a Afolabi, Saheed O. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Genetic Engineering and Biotechnology |d Amsterdam [u.a.] : Elsevier, 2011 |g 19(2021), 1 vom: 05. Aug. |w (DE-627)SPR038869144 |w (DE-600)2637420-1 |x 2090-5920 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:1 |g day:05 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43141-021-00209-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 1 |b 05 |c 08 | ||